Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance.
BACKGROUND
Functional magnetic resonance imaging (MRI) seems to be a useful tool for prostate cancer (PCa) detection in patients with a previous negative biopsy but persistently increased prostate-specific antigen (PSA) values. Additionally, it enables correct cancer localization in patients with known PCa under active surveillance to avoid misclassification on repeat biopsies. Nevertheless, suspicious lesions on MRI findings need verification by biopsy. The aim of the present study was to establish a standardized functional prostate MRI reporting scheme.


METHODS
Prostate MRI with T(2)-weighted images, T(1)-weighted images, diffusion-weighted imaging, and dynamic contrast-enhanced MRI of 56 consecutive patients were performed on a 3-T scanner. Patients with prior negative random transrectal ultrasound (TRUS)-guided biopsy and continuous suspicion for PCa as well as patients under active surveillance were included. The MRI localization report of suspicious lesions followed a standardized scheme. TRUS-guided random biopsy with addition of targeted biopsy cores was performed afterwards based on the structured report.


RESULTS
Of the 56 patients, 18 had suspicious MRI findings and subsequently underwent repeat biopsy under guidance of the standardized localization scheme. PCa was documented in 72% (13/18).


CONCLUSIONS
A standardized reporting scheme of suspicious findings on prostate MRI leads to higher success rates as compared to standard random TRUS-guided biopsy.
Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany. Michael.Quentin @ med.uni-duesseldorf.de
M
M
Quentin
D
D
Blondin
J
J
Klasen
J
J
Schek
C
C
Buchbender
F R
FR
Miese
G
G
Antoch
D
D
Barski
P
P
Albers
C
C
Arsov
D000328:Adult; D000368:Aged; D001706:Biopsy; D003287:Contrast Media; D038524:Diffusion Magnetic Resonance Imaging / Q000592:standards*; D004282:Documentation / Q000592:standards*; D005188:False Negative Reactions; D005189:False Positive Reactions; D005568:Forms and Records Control / Q000592:standards*; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D015203:Reproducibility of Results; D015854:Up-Regulation; D057832:Watchful Waiting
D003287:Contrast Media; D017430:Prostate-Specific Antigen